# HeartBeam, Inc.: overview

BEATW · Nasdaq · CIK 1779372 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/beatw.md) · [Financials](/companies/beatw/financials.md) · [Filings](/companies/beatw/filings.md) · [Insiders](/companies/beatw/insiders.md)

Revenue is not reported in this company’s XBRL financial statements.

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.19)](/filings/0001193125-25-280112.md) | not reported | [(0.18)](/filings/0001193125-26-221565.md) | [(0.15)](/filings/0001193125-26-349121.md) | [(0.15)](/filings/0001193125-25-280112.md) | not reported | [(0.12)](/filings/0001193125-26-221565.md) | [(0.10)](/filings/0001193125-26-349121.md) |
| Free cash flow | $k | [(3,409) d](/filings/0001193125-25-280112.md) | [(4,152) d](/filings/0001193125-26-104080.md) | [(4,477)](/filings/0001193125-26-221565.md) | [(3,547) d](/filings/0001193125-26-349121.md) | [(3,242) d](/filings/0001193125-25-280112.md) | [(3,322) d](/filings/0001193125-26-104080.md) | [(3,856)](/filings/0001193125-26-221565.md) | [(3,591) d](/filings/0001193125-26-349121.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(1.03)](/filings/0001779372-23-000006.md) | [(1.59)](/filings/0001779372-24-000002.md) | [(0.72)](/filings/0001628280-25-012614.md) | [(0.73)](/filings/0001193125-26-104080.md) | [(0.62)](/filings/0001193125-26-104080.md) |
| Free cash flow | $m | not reported | [(9.9)](/filings/0001779372-24-000002.md) | [(12.3)](/filings/0001628280-25-012614.md) | [(14.7)](/filings/0001193125-26-104080.md) | [(14.6)](/filings/0001193125-26-104080.md) |

- Revenue. XBRL not reported.
- Gross margin (gross profit / revenue). XBRL not reported.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/beatw/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.6m | 2,137,512 |  | Added +939,719 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $740.9k | 987,837 |  | Added +89,516 |
| [CORSAIR CAPITAL MANAGEMENT, L.P.](/funds/1276470.md) | 2026-06-30 | $684.4k | 912,500 |  | New +912,500 |
| [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $468.8k | 625,000 |  | New +625,000 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $359.6k | 479,386 |  | Added +102,174 |
| [Smith Salley Wealth Management](/funds/1482012.md) | 2026-06-30 | $275.7k | 367,647 |  | Unchanged |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $224.2k | 298,917 |  | Reduced −36,272 |
| [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $206.1k | 274,818 |  | Added +124,756 |
| [Sigma Planning Corp](/funds/1449126.md) | 2026-06-30 | $185.8k | 247,700 |  | Added +115,150 |
| [Beacon Pointe Advisors, LLC](/funds/1744317.md) | 2026-06-30 | $185.3k | 247,058 |  | Reduced −400 |

## Recent filings

[All 271 filings](/companies/beatw/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-14 | 21:01 ET | [8-K](/filings/0001213900-26-090241.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001213900-26-090241 |
| 2026-08-13 | 20:30 ET | [SCHEDULE 13D/A](/filings/0001213900-26-089158.md) | Ownership report, active investor, amended | 0001213900-26-089158 |
| 2026-08-13 | 20:02 ET | [10-Q](/filings/0001193125-26-349121.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349121 |
| 2026-08-06 | 22:16 ET | [8-K/A](/filings/0001213900-26-085822.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-085822 |
| 2026-08-03 | 20:15 ET | [8-K](/filings/0001213900-26-084622.md) | 5.07 Shareholder vote results | 0001213900-26-084622 |
| 2026-07-02 | 20:15 ET | [8-K](/filings/0001213900-26-074979.md) | 3.01 Delisting notice | 0001213900-26-074979 |
| 2026-06-24 | 21:28 ET | [8-K](/filings/0001213900-26-071605.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001213900-26-071605 |
| 2026-06-22 | 20:15 ET | [8-K](/filings/0001213900-26-070628.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-070628 |
| 2026-06-18 | 21:00 ET | [DEF 14A](/filings/0001193125-26-276053.md) | Proxy statement, period 2026-06-18 | 0001193125-26-276053 |
| 2026-05-13 | 20:02 ET | [10-Q](/filings/0001193125-26-221565.md) | Quarterly report, period 2026-03-31 | 0001193125-26-221565 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-104080.md), filed Mar 12, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1779372
- Tickers: BEATW, BEAT
- Exchange: Nasdaq
- SIC code: 3841 Surgical & Medical Instruments & Apparatus
- State of incorporation: DE
- Filer category: <br>Emerging growth company

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.